Search company, investor...

Ventus Therapeutics

Founded Year



Grant | Alive

Total Raised


About Ventus Therapeutics

Ventus Therapeutics is a biopharmaceutical company that discovers and develops small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. Its structural immunology platform offers insight into mechanisms and molecular structures, combining proprietary protein engineering capabilities that elucidate innate immune mechanisms, and leading-edge rational and structure-based drug design tools. It was founded in 2019 and is based in Montreal, Quebec.

Headquarters Location

7150 Frederick-Banting

Montreal, Quebec, H9S 2A1,



Missing: Ventus Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ventus Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Ventus Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Ventus Therapeutics in 1 CB Insights research brief, most recently on Aug 5, 2021.

Expert Collections containing Ventus Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ventus Therapeutics is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Ventus Therapeutics Patents

Ventus Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Immune system, Immunology, LRR proteins, Rare diseases


Application Date


Grant Date



Related Topics

Clusters of differentiation, Immune system, Immunology, LRR proteins, Rare diseases



Latest Ventus Therapeutics News

Ventus Therapeutics Chief Scientific Officer Michael Crackower, Ph.D., to Present on ReSOLVE™ Platform at Next Generation Undruggable Conference

Oct 6, 2022

October 06, 2022 08:00 AM Eastern Daylight Time WALTHAM, Mass. & MONTREAL--( BUSINESS WIRE )-- Ventus Therapeutics, Inc. , a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today that its Chief Scientific Officer, Michael Crackower, Ph.D., will present a case study on the company’s proprietary drug discovery platform, ReSOLVE, at the third annual Next Generation Undruggable conference, taking place on October 11 in Boston, Mass. Details of the presentation: Title: Case Study: Application of the ReSOLVE Platform to Identify Druggable Pockets and Conduct Virtual Screening in the Absence of any Known Chemical Matter Date: Oct. 11, 2022, 4:20 pm EDT Presenter: Michael Crackower, Ph.D., Chief Scientific Officer, Ventus Therapeutics Location: The Bostonian Hotel, Boston, Mass. The ReSOLVE platform provides Ventus with a differentiated capability to analyze and visualize protein targets at a level of detail not available to others, leading to the identification of promising binding pockets that adopt many transient conformations. With these unique insights, Ventus can create dynamic blueprints, referred to as hydrocophores, that provide specific guidance on the size, shape, and polarity of each potential binding site and, using the hydrocophores, screen billions of compounds with great accuracy to generate novel chemical matter. As an end-to-end drug discovery platform, ReSOLVE allows Ventus to advance novel differentiated small molecules in a much more time- and cost-efficient manner than conventional drug discovery approaches. For more information about Ventus’ ReSOLVE platform and drug pipeline, visit: . For more information on the Annual Next Generation Undruggable event, visit: . About Ventus Therapeutics Ventus Therapeutics is a biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets, with an initial focus on immunology, inflammation and neurology. The Company’s proprietary drug discovery platform ReSOLVE gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic blueprints that can guide the development of differentiated small molecule medicines. The Company’s lead programs target key innate immune modulators, including NLRP3 and cGAS. The Company aims to use its ReSOLVE platform to improve the way medicines are discovered and developed, with the ultimate goal of restoring the health of people facing serious illnesses. For more information, please visit and engage with Ventus on Twitter @Ventus_Tx or on LinkedIn . Forward-Looking Statements This press release contains forward-looking statements about future expectations, plans and prospects, including, but not limited to, statements related to the anticipated benefits of the executive leadership team, Ventus’ business strategy, current programs, future results of operations, and financial position. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the timing, progress, and results of preclinical and clinical studies involving its development programs; the results of its earlier studies not being predictive of future results; its ability to enhance the ReSOLVE platform; its ability to continue to obtain funding for its operations and to implement its business strategy; the impact of the COVID-19 pandemic on its business and its efforts to address the impact on its business; anticipated developments related to its competitors and its industry; the performance of third-party service providers, including suppliers and manufacturers; and its ability to obtain, maintain, and protect its intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ventus undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or otherwise. Contacts

Ventus Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ventus Therapeutics Rank

Ventus Therapeutics Frequently Asked Questions (FAQ)

  • When was Ventus Therapeutics founded?

    Ventus Therapeutics was founded in 2019.

  • Where is Ventus Therapeutics's headquarters?

    Ventus Therapeutics's headquarters is located at 7150 Frederick-Banting, Montreal.

  • What is Ventus Therapeutics's latest funding round?

    Ventus Therapeutics's latest funding round is Grant.

  • How much did Ventus Therapeutics raise?

    Ventus Therapeutics raised a total of $300M.

  • Who are the investors of Ventus Therapeutics?

    Investors of Ventus Therapeutics include U.S. Department of Defense, Google Ventures, Versant Ventures, RA Capital Management, Cormorant Asset Management and 9 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.